Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 5, 2012, Pages 691-696

  Zhang, Yong ^a   Huang, Tao ^a   Hu, Yi ^b   Wang, Yu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Gastroenterology   (China)

Author keywords

CD40; Human glioma cells; NF B signaling pathway

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTIGENS, CD40; CD40 LIGAND; CELL PROLIFERATION; CELLS, CULTURED; GLIOMA; HUMANS; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84870539609     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-1019-1     Document Type: Article

References (17)

1. Harnett MM. CD40: a growing cytoplasmic tale. Sci STKE, 2004, 2004(237):pe25
2. Geldart T, Illidge T. Anti-CD40 monoclonal antibody. Leuk Lymphoma, 2005, 46(8):1105-1113 (Pubitemid 41087014)
3. Wischhusen J, Schneider D, Mittelbronn M, et al. Death receptor-mediated apoptosis in human malignant glioma cells: modulation by the CD40/CD40L system. J Neuroimmunol, 2005, 162(1-2):28-42
4. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J, 1989, 8(5):1403-1410 (Pubitemid 19274364)
5. Thomas WD, Smith MJ, Si Z, et al. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer, 1996, 68(6):795-801 (Pubitemid 27062043)
6. Chen K, Huang J, Gong W, et al. CD40/CD40L Dyad in the Inflammatory and Immune Responses in the Central Nervous System. Cell Mol Immunol, 2006, 3(3):163-169
7. Airoldi I, Lualdi S, Bruno S, et al. Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. Brit J Cancer, 2003, 88(10): 1527-1536 (Pubitemid 36713777)
8. Hirano A, Longo DL, Taub DD, et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood, 1999, 93(9):2999-3007 (Pubitemid 29200792)
9. Hakkarainen T, Hemminki A, Pereboev AV, et al. CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res, 2003, 9(2): 619-624 (Pubitemid 36182593)
10. Hill SC, Youde SJ, Man S, et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol, 2005, 174(1):41-50 (Pubitemid 40007390)
11. Ehtesham M, Kabos P, Gutierrez MA, et al. Intratumoral Dendritic Cell Vaccination Elicits Potent Tumoricidal Immunity Against alignant Glioma in Rats. J Immunother, 2003, 26(2):107-116 (Pubitemid 36292781)
12. Imbeault M, Ouellet M, Tremblay MJ. Efficient magnetic bead-based separation of HIV-1-infected cells using an improved reporter virus system reveals that p53 up-regulation occurs exclusively in the virus-expressing cell population. Virology, 2009, 393(1): 160-167
13. Pang Y, Cai Z, Rhodes PG. Analysis of genes differentially expressed in astrocytes stimulated with lipopolysaccharide using cDNA arrays. Brain Res, 2001, 914(1-2):15-22 (Pubitemid 32905427)
14. Sui Z, Sniderhan LF, Schifitto G, et al. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol, 2007, 178(5):3226-3236 (Pubitemid 46333205)
15. Sui Z, S. Fan L, Sniderhan, E, et al. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol, 2006, 177(1): 702-711 (Pubitemid 43939185)
16. Benveniste EN, Nguyen VT, Wesemann DR. Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav Immun. 2004, 18(1):7-12 (Pubitemid 37476278)
17. Niederberger E, Geisslinger G. The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J, 2008, 22(10):3432-3442